These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25211704)

  • 1. Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells.
    Andreoli M; Persico M; Kumar A; Orteca N; Kumar V; Pepe A; Mahalingam S; Alegria AE; Petrella L; Sevciunaite L; Camperchioli A; Mariani M; Di Dato A; Novellino E; Scambia G; Malhotra SV; Ferlini C; Fattorusso C
    J Med Chem; 2014 Oct; 57(19):7916-32. PubMed ID: 25211704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GTP is an allosteric modulator of the interaction between the guanylate-binding protein 1 and the prosurvival kinase PIM1.
    Persico M; Petrella L; Orteca N; Di Dato A; Mariani M; Andreoli M; De Donato M; Scambia G; Novellino E; Ferlini C; Fattorusso C
    Eur J Med Chem; 2015 Feb; 91():132-44. PubMed ID: 25081641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer.
    De Donato M; Mariani M; Petrella L; Martinelli E; Zannoni GF; Vellone V; Ferrandina G; Shahabi S; Scambia G; Ferlini C
    J Cell Physiol; 2012 Mar; 227(3):1034-41. PubMed ID: 21520077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GBP1 overexpression is associated with a paclitaxel resistance phenotype.
    Duan Z; Foster R; Brakora KA; Yusuf RZ; Seiden MV
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):25-33. PubMed ID: 16028104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIM1 controls GBP1 activity to limit self-damage and to guard against pathogen infection.
    Fisch D; Pfleiderer MM; Anastasakou E; Mackie GM; Wendt F; Liu X; Clough B; Lara-Reyna S; Encheva V; Snijders AP; Bando H; Yamamoto M; Beggs AD; Mercer J; Shenoy AR; Wollscheid B; Maslowski KM; Galej WP; Frickel EM
    Science; 2023 Oct; 382(6666):eadg2253. PubMed ID: 37797010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of quinones as novel PIM1 kinase inhibitors.
    Schroeder RL; Goyal N; Bratton M; Townley I; Pham NA; Tram P; Stone T; Geathers J; Nguyen K; Sridhar J
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3187-3191. PubMed ID: 27173800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indolyl-pyrrolone as a new scaffold for Pim1 inhibitors.
    Olla S; Manetti F; Crespan E; Maga G; Angelucci A; Schenone S; Bologna M; Botta M
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1512-6. PubMed ID: 19179076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phytoconstituents and Medicinal Plants for Anticancer Drug Discovery: Computational Identification of Potent Inhibitors of PIM1 Kinase.
    Anjum F; Mohammad T; Almalki AA; Akhtar O; Abdullaev B; Hassan MI
    OMICS; 2021 Sep; 25(9):580-590. PubMed ID: 34448628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights from Pim1 structure for anti-cancer drug design.
    Ogawa N; Yuki H; Tanaka A
    Expert Opin Drug Discov; 2012 Dec; 7(12):1177-92. PubMed ID: 23004574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guanylate-Binding Protein-1 protects ovarian cancer cell lines but not breast cancer cell lines from killing by paclitaxel.
    Tipton AR; Nyabuto GO; Trendel JA; Mazur TM; Wilson JP; Wadi S; Justinger JS; Moore GL; Nguyen PT; Vestal DJ
    Biochem Biophys Res Commun; 2016 Sep; 478(4):1617-23. PubMed ID: 27590579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D QSAR studies, molecular docking and ADMET evaluation, using thiazolidine derivatives as template to obtain new inhibitors of PIM1 kinase.
    Aouidate A; Ghaleb A; Ghamali M; Ousaa A; Choukrad M; Sbai A; Bouachrine M; Lakhlifi T
    Comput Biol Chem; 2018 Jun; 74():201-211. PubMed ID: 29635214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors.
    Bogusz J; Zrubek K; Rembacz KP; Grudnik P; Golik P; Romanowska M; Wladyka B; Dubin G
    Sci Rep; 2017 Oct; 7(1):13399. PubMed ID: 29042609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
    Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
    Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.
    Darby RA; Unsworth A; Knapp S; Kerr ID; Callaghan R
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):853-64. PubMed ID: 26351135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.
    Nakano H; Saito N; Parker L; Tada Y; Abe M; Tsuganezawa K; Yokoyama S; Tanaka A; Kojima H; Okabe T; Nagano T
    J Med Chem; 2012 Jun; 55(11):5151-64. PubMed ID: 22540945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GBP1 promotes erlotinib resistance via PGK1‑activated EMT signaling in non‑small cell lung cancer.
    Cheng L; Gou L; Wei T; Zhang J
    Int J Oncol; 2020 Sep; 57(3):858-870. PubMed ID: 32582960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance.
    Holder SL; Abdulkadir SA
    Curr Cancer Drug Targets; 2014; 14(2):105-14. PubMed ID: 24274399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia.
    Yuan K; Ji M; Xie S; Qiu Z; Chen W; Min W; Xia F; Zheng M; Wang X; Li J; Hou Y; Kuang W; Wang L; Gu W; Li Z; Yang P
    J Med Chem; 2022 Jan; 65(1):857-875. PubMed ID: 34958208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of pim1 kinase in complex with a pyrido[4,3-d]pyrimidine derivative suggests a unique binding mode.
    Lee SJ; Han BG; Cho JW; Choi JS; Lee J; Song HJ; Koh JS; Lee BI
    PLoS One; 2013; 8(7):e70358. PubMed ID: 23936194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New pyrazolopyrimidine derivatives with anticancer activity: Design, synthesis, PIM-1 inhibition, molecular docking study and molecular dynamics.
    Philoppes JN; Khedr MA; Hassan MHA; Kamel G; Lamie PF
    Bioorg Chem; 2020 Jul; 100():103944. PubMed ID: 32450389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.